MINNEAPOLIS

明尼阿波利斯

,

，

Sept. 23, 2026

2026年9月23日

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ:

/美通社/ -- Bio-Techne 公司（纳斯达克股票代码：

TECH

科技

) ('Bio-Techne'), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the 'Merger Agreement') at a Special Meeting of Shareholders held today..

全球生命科学工具、试剂和诊断产品供应商Bio-Techne宣布，在当日召开的股东特别会议上，Bio-Techne股东投票批准并通过了由德国达姆施塔特的默克集团（Merck KGaA）拟收购Bio-Techne的最终协议（即“合并协议”）。

'We are grateful to our shareholders for their strong support, which marks an important milestone toward completing the transaction,' said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. 'Joining Merck KGaA, Darmstadt, Germany will bring together our complementary and leading life sciences organizations while delivering substantial, near-term cash value to Bio-Techne shareholders.

“我们感谢股东们的大力支持，这标志着完成交易的一个重要里程碑，”Bio-Techne 总裁兼首席执行官 Kim Kelderman 表示。“加入位于德国达姆施塔特的默克集团（Merck KGaA），将把我们在生命科学领域互补且领先的组织汇聚在一起，同时为 Bio-Techne 股东带来可观的近期现金价值。”

The combined company will be uniquely positioned to support customers across the full spectrum of life science workflows from discovery and translational research through development, testing and commercial manufacturing.'.

合并后的公司将具备独特优势，能够支持客户覆盖生命科学全流程的工作流，涵盖从发现与转化研究到开发、测试及商业化生产。

The final voting results, as certified by the independent inspector of elections, will be reported in a Form 8-K filed with the U.S. Securities and Exchange Commission (the 'SEC').

最终的投票结果将由独立的选举监察人认证，并通过向美国证券交易委员会（“SEC”）提交的8-K表格进行披露。

In addition to shareholder approval, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the proposed transaction expired at 11:59 p.m., Eastern Time, on September 18, 2026. Bio-Techne continues to expect the transaction to close by late 2026 or early 2027, subject to satisfaction of customary closing conditions, including receipt of remaining required regulatory approvals..

除获得股东批准外，根据经修订的《1976年哈特-斯科特-罗迪诺反垄断改进法》规定的等待期已于2026年9月18日美国东部时间晚上11:59届满，该等待期与拟议交易相关。Bio-Techne仍预计交易将在2026年底或2027年初完成，前提是满足惯常的交割条件，包括获得剩余所需的监管批准。

About Bio-Techne

关于 Bio-Techne

Bio Techne Corporation (NASDAQ:

Bio-Techne 公司（纳斯达克股票代码：

TECH

科技

) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer focused brands: R&D Systems™, Bio Techne Spatial™, and Bio Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making.

）是一家总部位于明尼苏达州的全球性生命科学公司，正值赋能科学与诊断社区寻求更优答案的五十周年庆典。公司提供高质量试剂、分析仪器和精准诊断产品。其产品组合划分为三个以客户为中心的品牌：R&D Systems™、Bio Techne Spatial™ 和 Bio Techne Diagnostics™，体现了从科学发现到转化研究再到临床决策的科学旅程。

Bio Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories..

Bio-Techne 在全球 34 个地点开展业务，员工人数超过 3,000 人。在 2025 财年，公司净销售额超过 12 亿美元。其 50 多万种产品被全球的学术研究人员、生物制药和生物技术公司以及临床诊断实验室广泛使用。

For more information on Bio Techne, please visit

如需了解更多关于Bio Techne的信息，请访问

www.bio-techne.com

www.bio-techne.com

or follow the company on LinkedIn, X, or YouTube.

或在 LinkedIn、X 或 YouTube 上关注该公司。

Bio-Techne Contacts

Bio-Techne 联系方式

David Clair, Vice President Investor Relations

大卫·克莱尔，投资者关系副总裁

[email protected]

[email protected]

Media contacts:

媒体联系人：

Corporate Communications

企业传播

[email protected]

[email protected]

Joele Frank, Wilkinson Brimmer Katcher

乔尔·弗兰克、威尔金森·布里默·卡彻律师事务所

Kelly Sullivan / Jamie Moser

凯莉·沙利文 / 杰米·莫泽

+1 212-355-4449

+1 212-355-4449

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This communication may contain forward-looking statements based on current assumptions and forecasts made by Merck KGaA, Darmstadt, Germany or Bio-Techne Corporation management. Statements that include words such as 'anticipate,' 'expect,' 'should,' 'would,' 'intend,' 'plan,' 'project,' 'seek,' 'believe,' 'will,' and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements.

本沟通材料可能包含基于德国达姆施塔特默克公司（Merck KGaA, Darmstadt, Germany）或Bio-Techne Corporation管理层当前假设和预测的前瞻性陈述。包含“预计”、“预期”、“应当”、“将会”、“打算”、“计划”、“规划”、“寻求”、“相信”、“将”等词语，并与未来事件或未来经营或财务表现相关的陈述，通常用于识别前瞻性陈述。

All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. Actual results could differ materially from those projected or forecasted in the forward-looking statements. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation or development and the estimates given here.

本通讯中除涉及历史信息或当前状况的陈述外，所有陈述均为前瞻性陈述。实际结果可能与前瞻性陈述中预测或预计的结果存在重大差异。各种已知和未知的风险、不确定性及其他因素可能导致实际未来业绩、财务状况或发展与本文所载估计存在重大差异。

These factors include the following: Merck KGaA, Darmstadt, Germany's ability to successfully complete the proposed acquisition of Bio-Techne or realize the anticipated benefits of the proposed transaction in the expected timeframes or at all; Merck KGaA, Darmstadt, Germany's ability to successfully integrate Bio-Techne's operations into those of Merck KGaA, Darmstadt, Germany, given such integration may be more difficult, time-consuming or costly than expected; the failure of any of the conditions to the proposed transaction to be satisfied; the possibility that competing offers or acquisition proposals for Bio-Techne will be made; revenues following the proposed transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, custo.

这些因素包括以下方面：德国达姆施塔特的默克公司（Merck KGaA）能否成功完成对Bio-Techne的拟议收购，或在预期时间内（或根本）实现该拟议交易的预期效益；鉴于整合过程可能比预期更困难、更耗时或成本更高，德国达姆施塔特的默克公司能否成功将Bio-Techne的业务整合至其自身业务中；拟议交易的任何先决条件未能得到满足；可能出现针对Bio-Techne的竞争报价或收购提案；交易完成后的收入可能低于预期；运营成本增加、客户流失及业务中断（包括但不限于在维持与员工、客户的关系方面遇到的困难）。

https://www.emdgroup.com/en

https://www.emdgroup.com/zh

or in Bio-Techne's Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2026 and Bio-Techne's other filings with the SEC, which are available at

或参见Bio-Techne向美国证券交易委员会（SEC）提交的截至2026年6月30日财政年度的Form 10-K年度报告，以及Bio-Techne向SEC提交的其他文件，这些文件可在以下网址获取：

http://www.sec.gov

http://www.sec.gov

and on Bio-Techne's website at

以及在 Bio-Techne 网站上，网址为

https://www.bio-techne.com

https://www.bio-techne.com

. Except as otherwise required by law, neither Merck KGaA, Darmstadt, Germany nor Bio-Techne assumes any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof..

除非法律另有规定，默克公司（Merck KGaA，德国达姆施塔特）和Bio-Techne均不承担任何更新这些前瞻性陈述或使其与未来事件或发展保持一致的责任。提醒读者不要过度依赖这些仅截至本文发布之日的前瞻性陈述。

SOURCE Bio-Techne Corporation

来源：Bio-Techne 公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示